
News|Videos|July 3, 2024
Monitoring Patients With Mild/Moderate Multiple Sclerosis
The key opinion leaders provide recommendations on the optimal frequency for evaluating disease progression in patients with mild to moderate MS, emphasizing effective monitoring methods and the most appropriate tools for best clinical practice.
Advertisement
Episodes in this series

How frequently should patients with mild to moderate MS be evaluated for disease activity and progression?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup
2
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis
3
Ractigen Completes Enrollment for RAG-17 in SOD1-ALS, Tanruprubart Shows Rapid Responses in GBS, Building a Multidisciplinary SMA Clinic
4
CN045 Promotes Oligodendrocyte Maturation, Modest Remyelination in Preclinical MS Study
5









